Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis

Clinical Nephrology

Volumn 82, Issue 5, 2014, Pages 326-331

  Povey, Hannah ^a   Vundru, Rahul ^a   Junglee, Naushad ^a   Jibani, Mahdi ^a  

^a YSBYTY GWYNEDD   (United Kingdom)

Author keywords

Acute kidney injury; Atypical hemolytic uremic syndrome; Eculizumab; Hemodialysis; Thromobotic microangiopathy

Indexed keywords

AMLODIPINE; CREATININE; ECULIZUMAB; ETHINYLESTRADIOL; FRESH FROZEN PLASMA; FUROSEMIDE; LABETALOL; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; NORELGESTROMIN; PENICILLIN DERIVATIVE; RAMIPRIL; VALPROIC ACID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; ALLERGIC GLOMERULONEPHRITIS; ANURIA; ARTICLE; BRAIN EDEMA; CASE REPORT; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; CRYSTALLOID; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GASTROENTERITIS; GENETIC ANALYSIS; HEADACHE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; KIDNEY FUNCTION; KIDNEY INJURY; LONG TERM CARE; LUNG EDEMA; MAINTENANCE DRUG DOSE; MALAISE; MENORRHAGIA; PLASMA TRANSFUSION; PLASMAPHERESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; SKIN BRUISING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; YOUNG ADULT; ACUTE KIDNEY INJURY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ALTERNATIVE PATHWAY; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT PATHWAY, ALTERNATIVE; FEMALE; HUMANS; PLASMA EXCHANGE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; RENAL DIALYSIS; YOUNG ADULT;

EID: 84909590646     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107958     Document Type: Article

References (20)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361: 1676-1687.
2. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6: 60.
3. Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol. 2012; 35: 394-400.
4. Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med. 2012; 70: 121-129.
5. Malina M, Roumenina LT, Seeman T, Le Quintrec M, Dragon-Durey MA, Schaefer F, Fremeaux-Bacchi V. Genetics of hemolytic uremic syndromes. Presse Med. 2012; 41: e105-e114.
6. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006; 108: 1267-1279.
7. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5: 1844-1859.
8. Food and Drug Administration. Prescribing information for Soliris® (eculizumab). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2011/125166s172lbl.pdf. Accessed Oct 2012.
9. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012; 8: 643-657.
10. Kavanagh D, Goodship THJ. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology (Am Soc Hematol Educ Program). 2011; 2011: 15-20.
11. Hauglustaine D, Vanrenterghem Y, Michielsen OP, van Damme B. Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome. Lancet. 1981; 1: 328-329.
12. Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011; 26: 613-619.
13. Duran CE, Blasco M, Maduell F, Campistol JM. Rescue therapy with eculizumab in a transplant recipient with atypical hemolytic-uraemic syndrome. Clin Kidney J. 2012; 0: 1-3.
14. Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012; 27: 2323-2326.
15. Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss K, Pazdur R. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008; 13: 993-1000.
16. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011; 117: 6786-6792.
17. Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, Khursigara G, Fu CL, Omine M, Browne P, Rosse W. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010; 85: 553-559.
18. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc. 2010; 42: 4353-4355.
19. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med. 2003; 24: 607-622.
20. Bagdasarian N, Heung M, Malani PN. Infectious complications of dialysis access devices. Infect Dis Clin North Am. 2012; 26: 127-141.